Answers are grounded in this paper and cite their sources.
Immune checkpoint blockade (ICB) has transformed cancer therapy, yet clinical benefit remains highly heterogeneous. Although the intratumoral immune landscape is central to understanding ICB efficacy, peripheral T-cell clonal dynamics highlight the importance of immune processes beyond the tumor microenvironment. Lymph nodes (LNs), particularly tumor-draining lymph nodes (TDLNs), contribute to systemic antitumor immunity through antigen presentation, T-cell priming, and the maintenance of tumor-reactive precursor populations. However, LNs are not functionally equivalent. In this Review, we examine the multiscale determinants of LN heterogeneity, including intranodal organization, tissue-specific immune imprinting, and regional lymphatic connectivity, and discuss tumor-induced remodeling and treatment-associated changes in LN function. We then consider the implications of LN heterogeneity for systemic antitumor immunity, immunotherapy responses, and potential clinical applications, including biomarker development and LN-directed therapeutic strategies. Finally, we propose testable hypotheses to guide future mechanistic and clinical investigations.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: